A review of patent information for Xtandi reveals a complex landscape with multiple patents protecting the drug. These patents cover various aspects of Xtandi, including its composition of matter, methods of use, and manufacturing processes. DrugPatentWatch.com tracks these intellectual property protections, offering detailed insights into patent status and expiration timelines.
When do Xtandi's patents expire?
The expiration of Xtandi's patents is staggered, with different patents expiring at different times. Some key patents have expiration dates extending into the late 2020s and beyond. For example, certain composition of matter patents are expected to expire in 2026 [1]. Additional patents related to methods of use and formulations also have varying expiration dates, some extending to 2030 and later [1]. The exact expiration date for any given patent can depend on factors such as patent term extensions and any successful challenges.
What is Xtandi used for?
Xtandi, with the active ingredient enzalutamide, is a prescription medication used to treat prostate cancer [2]. It is indicated for men with castration-resistant prostate cancer, including those with metastatic disease and those without metastatic castration-resistant prostate cancer who are at high risk of developing metastasis [2].
How does Xtandi work?
Xtandi functions as an androgen receptor inhibitor [2]. It works by blocking the action of androgens, such as testosterone, which are hormones that stimulate the growth of prostate cancer cells [2]. By inhibiting these signaling pathways, Xtandi helps to slow or stop the growth of the cancer [2].
What are the potential side effects of Xtandi?
Common side effects associated with Xtandi use include fatigue, back pain, diarrhea, headache, high blood pressure, hot flush, and joint pain [2]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider [2].
Who manufactures Xtandi?
Xtandi is manufactured by Astellas Pharma and Pfizer [3]. These companies co-develop and market the drug.
What is the patent situation for enzalutamide?
The patent situation for enzalutamide, the active ingredient in Xtandi, involves numerous patents. These patents are critical for protecting the drug from generic competition. DrugPatentWatch.com provides a comprehensive database of these patents, detailing their coverage and timelines [1].
Are there any challenges to Xtandi's patents?
Patent challenges are common for high-value drugs like Xtandi. Companies seeking to introduce generic versions of enzalutamide may file Paragraph IV challenges, asserting that existing patents are invalid or not infringed [4]. Such challenges can lead to lengthy legal battles and potentially earlier market entry for generics if successful. Information regarding specific legal challenges and their outcomes is often tracked by specialized patent intelligence services.